Trichy Daily

CDKL5 Deficiency Disorder (CDD) Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

CDKL5 Deficiency Disorder (CDD) Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 12
14:05 2020
CDKL5 Deficiency Disorder (CDD) Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder, historical and forecasted epidemiology as well as the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

CDKL5 Deficiency Disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) caused by mutations in the CDKL5 gene.

 

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Insights

  • The total CDKL5 Deficiency Disorder prevalent population in 7MM in 2017 was 16,397  
  • The total CDKL5 Deficiency Disorder diagnosed prevalence in the United States in 2017 – 
    • 208 – males
    • 1,315 – females
    • Mainly eight types of clinical characteristics of CDD are observed in patients in 2017 :-    
      • 1,234 – Epileptic Spasms
      • 716 – Hypsarrhythmia
      • 1,142 – Cortical Visual Impairment
      • 1,218 – Hand Stereotypies
      • 1,317 – Gastrointestinal Symptoms
      • 1,080 – Constipation
      • 976 – Reflux
      • 1,295 – Sleep Difficulties   

 

CDKL5 Deficiency Disorder Market Insight

CDKL5 Deficiency Disorder market size in 7MM in 2017 was USD 5.95 Million

 

CDKL5 Deficiency Disorder Market Drivers

  • Understanding molecular biology of CDKL5 Deficiency Disorder (CDD)
  • Increased Awareness
  • Therapeutic Opportunities
  • Upsurge in Research and Development
  • Research beyond clinical trials

 

CDKL5 Deficiency Disorder Market Barriers

  • Treatment Resistant Seizures
  • Fewer Patients
  • Fewer Clinical Trials

 

Scope of the Report

  • The report covers the descriptive overview of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market

 

Request for sample pages

Table of contents

1. Key Insights

2. Executive Summary of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder

3. Competitive Intelligence Analysis for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder

4. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Market Overview at a Glance

4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Share (%) Distribution in 2017

4.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Share (%) Distribution in 2030

5. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment and Management

8.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Seven Major Market Analysis

13.1. Key Findings

13.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size in 7MM

13.3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in the United States

15.1.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Germany

15.3.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in France

15.4.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Italy

15.5.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Spain

15.6.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in the United Kingdom

15.7.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Japan

15.8.3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles